RYBREVANT (amivantamab) - Non-small cell lung cancer (NSCLC)

The clinical benefit of RYBREVANT (amivantamab) 1,600 mg and 2,240 mg solution for injection is moderate in the MA indication: “in combination with lazertinib for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations”. 

These medicinal products are range supplements that provide no clinical added value (CAV V) compared to the form already listed.